0000950170-24-080723.txt : 20240702 0000950170-24-080723.hdr.sgml : 20240702 20240702171717 ACCESSION NUMBER: 0000950170-24-080723 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240628 FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Casdin Eli CENTRAL INDEX KEY: 0001534264 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34180 FILM NUMBER: 241097026 MAIL ADDRESS: STREET 1: 1350 AVENUE OF THE AMERICAS STREET 2: SUITE 1140 CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: STANDARD BIOTOOLS INC. CENTRAL INDEX KEY: 0001162194 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 770513190 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502666000 MAIL ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: FLUIDIGM CORP DATE OF NAME CHANGE: 20011113 4 1 ownership.xml 4 X0508 4 2024-06-28 0001162194 STANDARD BIOTOOLS INC. LAB 0001534264 Casdin Eli C/O STANDARD BIOTOOLS INC. 2 TOWER PLACE, STE 2000 SOUTH SAN FRANCISCO CA 94080 true false true false false Common Stock 2024-06-28 4 A false 43128 0 A 2750744 D Common Stock 13939637 I Casdin Private Growth Equity Fund II, L.P. Common Stock 2744219 I By Casdin Private Growth Equity Fund, L.P. Common Stock 18870 I See footnote Common Stock 46730821 I Casdin Partners Master Fund, L.P Common Stock 545000 I Casdin Amplify Fund, LP Stock Option (Right to buy) 1.77 2024-06-28 4 A false 72213 0 A 2034-06-28 Common Stock 72213 72213 D Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 28, 2025 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Includes 2,604,060 shares of common stock received in a pro rata distribution for no consideration by C-LSH II LLC in accordance with the exemptions afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. The securities are indirectly owned by Eli Casdin who has voting and investment discretion with respect to the securities. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. The securities are owned directly by Casdin Amplify Fund, LP ("Amplify") and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin and the GP. The Option becomes exercisable in twelve equal monthly installments beginning on July 28, 2024, subject to the Reporting Person's continued service through the applicable vesting date. The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. /s/ Eli Casdin by Agnieszka Gallagher, Attorney-in-Fact 2024-07-02